Gamida Cell is a cell therapy pioneer working to turn cells into powerful therapeutics. Our proprietary nicotinamide (NAM) technology enhances and expands cells to create potentially curative cell therapy products and candidates for patients with hematologic malignancies. Our allogeneic hematopoietic progenitor cell therapy was approved by the US FDA in April 2023. A multicenter Phase 1 study of our NK cell therapy candidate, GDA-201, is ongoing, with results expected in Q1 2024